Please assess the completion status of the following clinical trial:

Trial Title: Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Histologically or cytologically proven IIIB and IV NSCLC.~* No symptomatic uncontrolled brain metastasis~* Not suitable for platinum containing regimens if chemo-naive~* Performance status less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) Scale.~* Creatinine Clearance (CrCl) greater than or equal to 45 milliliters per min (mL/min)~Exclusion Criteria~* Prior radiation to greater than 25% of bone marrow~* Inability to interrupt Aspirin at doses of greater than 1.3 grams/day or non-steroidal anti-inflammatory agents for a 5-day period.~* Presence of clinically relevant third-space fluid collections not controllable.~* Significant cardiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed - Before Protocol Amendment (Type: EXPERIMENTAL): None
- Pemetrexed - After Protocol Amendment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).